David James Lennon Sells 9,689 Shares of Aadi Bioscience, Inc. (NASDAQ:AADI) Stock

Aadi Bioscience, Inc. (NASDAQ:AADI) CEO David James Lennon sold 9,689 shares of the stock in a transaction dated Thursday, October 3rd. The shares were sold at an average price of $1.94, for a total value of $18,796.66. Following the sale, the chief executive officer now owns 22,869 shares of the company’s stock, valued at $44,365.86. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Aadi Bioscience Trading Up 1.0 %

NASDAQ:AADI opened at $1.94 on Friday. The company has a 50-day moving average price of $1.70 and a 200-day moving average price of $1.77. The stock has a market cap of $47.63 million, a price-to-earnings ratio of -0.76 and a beta of 0.70. Aadi Bioscience, Inc. has a 12 month low of $1.21 and a 12 month high of $5.70.

Aadi Bioscience (NASDAQ:AADI) last posted its quarterly earnings data on Wednesday, August 7th. The company reported ($0.54) earnings per share for the quarter, beating the consensus estimate of ($0.71) by $0.17. Aadi Bioscience had a negative return on equity of 66.67% and a negative net margin of 274.77%. The business had revenue of $6.18 million for the quarter, compared to analysts’ expectations of $6.33 million. During the same period in the previous year, the firm posted ($0.67) EPS. Equities analysts forecast that Aadi Bioscience, Inc. will post -2.02 EPS for the current fiscal year.

Hedge Funds Weigh In On Aadi Bioscience

A number of institutional investors have recently added to or reduced their stakes in AADI. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Aadi Bioscience in the 2nd quarter worth about $37,000. Marquette Asset Management LLC bought a new stake in Aadi Bioscience during the first quarter worth about $135,000. Finally, Acuitas Investments LLC grew its holdings in Aadi Bioscience by 10.8% in the second quarter. Acuitas Investments LLC now owns 352,483 shares of the company’s stock worth $515,000 after purchasing an additional 34,344 shares during the period. Institutional investors own 52.08% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently weighed in on AADI shares. TD Cowen lowered Aadi Bioscience from a “buy” rating to a “hold” rating in a research note on Wednesday, August 21st. Piper Sandler lowered shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and cut their price target for the stock from $5.00 to $1.75 in a report on Tuesday, August 27th. HC Wainwright restated a “neutral” rating on shares of Aadi Bioscience in a research report on Wednesday, August 21st. Piper Sandler Companies lowered shares of Aadi Bioscience from an “overweight” rating to a “neutral” rating and set a $1.75 target price for the company. in a report on Tuesday, August 27th. Finally, Jefferies Financial Group downgraded Aadi Bioscience from a “buy” rating to a “hold” rating and reduced their price target for the company from $11.00 to $1.50 in a report on Wednesday, August 21st. Five investment analysts have rated the stock with a hold rating, According to MarketBeat.com, the company has a consensus rating of “Hold” and an average target price of $10.25.

Aadi Bioscience Company Profile

Aadi Bioscience, Inc, a biopharmaceutical company, engages in developing and commercializing precision therapies for genetically defined cancers with alterations in mTOR pathway genes. Its lead drug product candidate comprises FYARRO, a form of sirolimus protein-bound particles for injectable suspension for the treatment in adult patients with advanced unresectable or metastatic malignant PEComa.